Share on StockTwits

Supernus Pharmaceuticals (NASDAQ:SUPN) is set to post its Q214 quarterly earnings results on Monday, August 11th. Analysts expect Supernus Pharmaceuticals to post earnings of ($0.16) per share and revenue of $19.85 million for the quarter.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) opened at 8.15 on Friday. Supernus Pharmaceuticals has a 1-year low of $5.84 and a 1-year high of $11.47. The stock’s 50-day moving average is $9.83 and its 200-day moving average is $9.23. The company’s market cap is $342.7 million.

On the ratings front, analysts at Jefferies Group reiterated a “hold” rating on shares of Supernus Pharmaceuticals in a research note on Thursday, May 15th. They now have a $9.00 price target on the stock.

Supernus Pharmaceuticals, Inc (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.